Patheon Inc (TSX:PTI), a provider of drug development and manufacturing services, has agreed to be taken private in a deal that values the company at around US$1.4 billion.

Shares of Patheon NV, a JLL Partners-backed provider of outsourced pharmaceutical development and manufacturing services, traded at $24.29 late Thursday morning after the company on Wednesday ...

Contacts. Patheon For investors: Tyler Gronbach, +1-919-226-3201 Vice President, Investor Relations, Corporate Communications or For media: Mari Mansfield, +1-919-226-3137 Senior Director ...

Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, today unveiled its new brand identity, reflecting the ...

Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has closed the previously announced transaction to acquire ...

Patheon, which has 1200 employees at its Greenville plant, is being bought by Thermo Fisher Scientific, the companies announced today. Thermo Fisher will pay $7.2 billion for Patheon, which is a U ...

Patheon announces a definitive agreement to acquire a new manufacturing site in Florence, SC, from Roche. ADDING MULTIMEDIA Patheon to Acquire State-of-the-Art Manufacturing Site.

Patheon, which bought Agere Pharmaceuticals in March, plans to increase revenue from its Bend unit by 40 percent in the coming year, according to the summary. The company also plans to invest $5.7 ...

Thermo Fisher Scientific Inc. said Monday it has agreed to acquire Patheon N.V. for $35 a share, or $7.2 billion including $2 billion of net debt. Thermo Fisher, which offers services to help with ...

Patheon said in its recent SEC-1 that it will use the cash to repay all of its outstanding $550 million of Senior PIK toggle notes, pay-related fees, expenses and accrued interest.

NewCo would have combined annual sales of $2 billion, and be 51% owned by private-equity firm JLL Partners, with the remainder owned by DSM. JLL, which owns 55.7% of Patheon stock, will contribute ...

Patheon shareholders will receive $35 in cash per share, representing a 35% premium from Friday’s closing price of $26. Thermo Fisher will also assume about $2 billion of net debt.